US FTC alleges Ovation charged monopoly prices for heart drugs
This article was originally published in Scrip
The US Federal Trade Commissionhas challenged Ovation Pharmaceuticals' acquisition of Neoprofen (ibuprofen lysine injectable) three years ago, asserting it was anticompetitive and resulted in hospitals paying monopoly prices for the only two drugs approved to treat patent ductus arteriosus (PDA) in premature babies.
You may also be interested in...
Generic drugs program has approved almost 300 manufacturing changes to help shore up the supply chain, with some prior approval supplements being downgraded to ‘changes being effected’ supplements, FDA officials said at GDUFA III kick-off meeting.
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.
US FDA’s ‘may be effective’ standard for granting an emergency use authorization is expected to be comparable to the substantial evidence of effectiveness needed to support full licensure of a COVID-19 vaccine, although EUA allows for a more rapid review, agency officials say.